GURU.Markets stock price, segment price, and overall market index valuation
The company's share price HUGE
Hyzon Motors is a manufacturer of hydrogen fuel cell trucks. Its stock price is a story of high hopes colliding with reality. The chart reflects production problems, accounting scandals, and the slow development of hydrogen infrastructure.
Share prices of companies in the market segment - Pharma neurology
FSD Pharma is a Canadian biopharmaceutical company focused on developing drugs for the treatment of inflammatory diseases and central nervous system disorders. We have classified it in the Pharma: Neuroscience category. The chart below shows how the market views this complex biotech sector.
Broad Market Index - GURU.Markets
FSD Pharma is a Canadian biotech company developing drugs to treat inflammatory diseases of the central nervous system. As an innovator in this field, it is included in our GURU.Markets index. The chart below shows the overall market trend. See how FSD shares correlate with sentiment in the biotech sector.
Change in the price of a company, segment, and market as a whole per day
HUGE - Daily change in the company's share price HUGE
FSD Pharma Inc.'s daily share price fluctuations reflect the high volatility inherent in biotech companies. This metric measures the company's sensitivity to news about clinical trials of its drugs for neurological disorders.
Daily change in the price of a set of shares in a market segment - Pharma neurology
FSD Pharma is a biopharmaceutical company focused on developing drugs for the treatment of neurological diseases. Neurology is a risky area of research. The chart below illustrates the high volatility typical of the biotech sector, reflecting the stakes associated with HUGE developments.
Daily change in the price of a broad market stock, index - GURU.Markets
FSD Pharma is a biotech company working on treatments for neurological diseases. Its shares represent a venture capital bet on scientific success. Their high volatility, driven by expectations, contributes to the complex and multifaceted dynamics of the entire stock market.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization HUGE
FSD Pharma Inc.'s year-to-date performance tells the story of its diversified but high-risk portfolio. Its 12-month market cap reflects progress in its programs, from multiple sclerosis treatments to psychedelic-based developments, making its valuation highly sensitive to clinical trial news.
Annual dynamics of market capitalization of the market segment - Pharma neurology
FSD Pharma, a biotech company, develops drugs for the treatment of neurological diseases. Its performance is completely separate from the sector and depends on news about clinical trials. Its stock price will reflect investors' speculative belief in the potential of its unique scientific developments.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
FSD Pharma, a company researching drugs for neurological disorders, lives by the laws of the biotech sector. Its year-over-year market capitalization isn't a reflection of the economy, but rather a graph of investor hopes and disappointments based on clinical trial results. The success of a single trial can trigger explosive growth.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization HUGE
FSD Pharma is a biopharmaceutical company focused on CNS diseases. Its monthly performance is entirely dependent on the results of its clinical trials. Data on its key drugs is a binary outcome event for its stock.
Monthly dynamics of market capitalization of the market segment - Pharma neurology
This chart reflects the dynamics of the volatile biotech sector. For FSD Pharma, a clinical-stage company, it's the backdrop. Its movements demonstrate how investor expectations surrounding the results of its CNS drug trials are impacting the entire industry.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
FSD Pharma is a biopharmaceutical company developing drugs for the treatment of neurological diseases. Its value is determined by progress in clinical trials. The overall market chart provides only background information, while FSD Pharma's performance is driven by development news, which is typical in the biotech sector, where one result can change everything.
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization HUGE
FSD Pharma is a biopharmaceutical company focused on treating neurological disorders. Its weekly stock price, like that of many biotech companies, is volatile and dependent on clinical trial news.
Weekly dynamics of market capitalization of the market segment - Pharma neurology
FSD Pharma is a biopharmaceutical company focused on developing drugs for the treatment of neurological diseases. This is a complex and risky field. The chart below will help determine whether HUGE's share price movements are a reaction to its own clinical data or reflect general investor sentiment in this area.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
FSD Pharma is a pharmaceutical company. Its shares likely move based on product and research news rather than general market trends. The chart will help you assess this independence and volatility.
Market capitalization of the company, segment and market as a whole
HUGE - Market capitalization of the company HUGE
FSD Pharma's market capitalization chart is a volatile story of a biotech company that has shifted its focus from cannabis to developing drugs for neurological diseases. Its low valuation and speculative nature reflect the risks associated with its early stage research.
HUGE - Share of the company's market capitalization HUGE within the market segment - Pharma neurology
FSD Pharma is a Canadian biotechnology company. Its market share in the pharmaceutical sector is small, reflecting its focus on specific developments. The company's market capitalization dynamics reflect progress in clinical trials and investor perceptions of the prospects of its scientific research.
Market capitalization of the market segment - Pharma neurology
Here's a chart showing the biotech sector's market capitalization. FSD Pharma is a company researching anti-inflammatory drugs. Its market history is replete with strategic shifts, including a previous interest in cannabis. This is an example of how biotech companies are finding their way and the most promising areas for research.
Market capitalization of all companies included in a broad market index - GURU.Markets
FSD Pharma is a Canadian biopharmaceutical company focused on developing drugs for the treatment of neurological diseases. Its market capitalization reflects the potential of its scientific developments. The chart below shows the economic weight of companies at the forefront of neuroscience.
Book value capitalization of the company, segment and market as a whole
HUGE - Book value capitalization of the company HUGE
FSD Pharma's book value is its equity and intellectual property, which is focused on developing drugs to treat inflammatory diseases. The chart tells the story of a company that has radically shifted its strategy, moving away from cannabis and now investing its capital in more traditional pharmaceutical development.
HUGE - Share of the company's book capitalization HUGE within the market segment - Pharma neurology
FSD Pharma develops drugs for the treatment of neurological diseases. The chart shows its share of actual R&D assets. These are its laboratories where work is underway to create new drugs to combat inflammation in the central nervous system.
Market segment balance sheet capitalization - Pharma neurology
FSD Pharma is a biopharmaceutical company focused on neuroscience. Their value is created in the lab. Their book value chart reflects the value of their R&D base but fails to capture the potential value of their intellectual property.
Book value of all companies included in the broad market index - GURU.Markets
FSD Pharma's balance sheet includes laboratories and R&D centers for developing drugs targeting the endocannabinoid system. The chart shows how the company built its scientific and material foundation for its pharmaceutical research.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - HUGE
FSD Pharma is a Canadian biopharmaceutical company. Its tangible assets are small. The chart below visualizes investor expectations for its neuroscience developments. Market capitalization dynamics will depend entirely on progress in clinical trials.
Market to book capitalization ratio in a market segment - Pharma neurology
FSD Pharma is a biopharmaceutical company developing drugs for the treatment of inflammatory diseases. Its valuation depends on the success of its clinical programs and its ability to bring new drugs to market. The chart reflects the high risk and expectations associated with early-stage biotech development.
Market to book capitalization ratio for the market as a whole
FSD Pharma is a biopharmaceutical company focused on neurological disorders. Its value depends almost entirely on the success of clinical trials. This chart demonstrates the vast gap between the market valuation, reflecting investor hopes for a breakthrough, and the modest book value of its assets.
Debts of the company, segment and market as a whole
HUGE - Company debts HUGE
FSD Pharma is a biotech company researching drugs for the treatment of neurological disorders. This chart shows its financial history, including previous forays into the cannabis sector. The company funds its ongoing research through existing cash flow and capital raisings.
Market segment debts - Pharma neurology
FSD Pharma is a Canadian biotech company focused on developing drugs for the treatment of neurological disorders. Like many companies in this sector, it is in the early stages of research. This chart clearly demonstrates the high financial risk and the need for ongoing capital raising.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio HUGE
FSD Pharma is a biopharmaceutical company. This chart shows its financial structure. For a research-stage company without stable revenue, debt is a significant risk that could jeopardize its ability to complete clinical trials.
Market segment debt to market segment book capitalization - Pharma neurology
FSD Pharma is a biopharmaceutical company specializing in developing drugs for neurological diseases. This chart shows the debt burden in the biotech sector. It is an indicator of the company's ability to finance its expensive clinical research and development in this complex area of medicine.
Debt to book value of all companies in the market
FSD Pharma is a biopharmaceutical company focused on developing drugs for the treatment of central nervous system diseases. This is one of the most complex and expensive areas of research. This chart of total market debt demonstrates how favorable the investment climate is overall for funding such long-term and risky projects.
P/E of the company, segment and market as a whole
P/E - HUGE
FSD Pharma is a Canadian biopharmaceutical company developing drugs for the treatment of neurological disorders. This chart reflects the high risks associated with early-stage clinical development. Its dynamics depend entirely on news of trial results.
P/E of the market segment - Pharma neurology
FSD Pharma is a biopharmaceutical company focused on developing drugs to treat inflammatory diseases of the central nervous system. This chart shows the average valuation for the pharmaceutical sector, reflecting how investors assess the risks and potential of companies operating in the complex field of neuroscience.
P/E of the market as a whole
FSD Pharma is a biopharmaceutical company developing drugs for the treatment of neurological disorders. Its valuation depends entirely on the success of its drugs in clinical trials. Overall market sentiment, reflected in this chart, is completely irrelevant. FSD Pharma's fate is decided in the lab.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company HUGE
FSD Pharma is a biopharmaceutical company focused on developing drugs for the treatment of inflammatory diseases of the central nervous system. This chart reflects market expectations for the success of its clinical programs. Future revenue depends on breakthroughs in the development of effective therapies for these complex conditions.
%20P%2FE%20HUGE&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-HUGE&v=1772565449986 "Chart of the company's future (projected) P/E HUGE")
Future (projected) P/E of the market segment - Pharma neurology
FSD Pharma is a biopharmaceutical company focused on developing drugs for the treatment of central nervous system diseases. The chart reflects average profitability expectations for the biotech sector. HUGE's position relative to this benchmark reflects the market's assessment of their scientific pipeline and ability to successfully conduct clinical trials to bring new drugs to market.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Pharma%20neurology&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Pharma-neurology&v=1772565450054 "Future (projected) P/E graph of the market segment - Pharma neurology")
Future (projected) P/E of the market as a whole
FSD Pharma is a Canadian biopharmaceutical company focused on developing drugs for the treatment of inflammatory diseases of the central nervous system. The company is researching compounds that target the endocannabinoid system. This chart of overall market expectations illustrates investor appetite for the risk associated with funding long and complex clinical trials in neuroscience.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772565450072 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit HUGE
FSD Pharma is a Canadian biopharmaceutical company developing drugs for the treatment of neurological disorders. Its financial schedule reflects clinical trial costs. Potential profitability depends on the success of its candidates for the treatment of diseases such as multiple sclerosis.
Profit of companies in the market segment - Pharma neurology
FSD Pharma is a Canadian biopharmaceutical company focused on developing drugs to treat inflammatory diseases of the central nervous system. This is a complex and promising area. This chart shows the overall profitability of the neuroscience pharmaceutical sector, reflecting investor interest and scientific progress in developing new treatments for diseases of the brain and nervous system.
Overall market profit
FSD Pharma develops drugs for the treatment of neurological diseases. Like most biotech companies in the research stage, its success depends on scientific breakthroughs and clinical trial results. The overall market situation, reflected in this chart, impacts its ability to raise capital to finance its operations.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company HUGE
FSD Pharma is a biopharmaceutical company developing drugs for the treatment of inflammatory diseases of the central nervous system. This chart reflects analysts' speculative expectations regarding the potential of its research projects, which are in early clinical trials.
%20profit%20of%20the%20company%20HUGE&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-HUGE&v=1772565450203 "Graph of future (projected) profit of the company HUGE")
Future (predicted) profit of companies in the market segment - Pharma neurology
FSD Pharma is a biopharmaceutical company developing drugs for the treatment of inflammatory diseases. Its research is focused on new therapeutic targets. The company's future depends on the success of clinical trials. This chart reflects forecasts for the entire pharmaceutical sector, providing context for assessing FSD Pharma's potential and risks in this complex field.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Pharma%20neurology&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Pharma-neurology&v=1772565450273 "Graph of future (predicted) profits of companies in a market segment - Pharma neurology")
Future (predicted) profit of the market as a whole
FSD Pharma is a biopharmaceutical company focused on neuroscience. Like other clinical-stage companies in this sector, its prospects depend on research success rather than macroeconomic indicators. This earnings curve is largely irrelevant for assessing its potential.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772565450308 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - HUGE
FSD Pharma is a biopharmaceutical company focused on developing drugs for the treatment of central nervous system disorders. With minimal revenue, its valuation, shown on this chart, is based on the potential of its scientific developments. The dynamics reflect news about the progress of clinical trials.
P/S market segment - Pharma neurology
FSD Pharma is a biopharmaceutical company focused on developing drugs for the treatment of inflammatory diseases. Future revenue depends on the success of its clinical programs. This pharma chart reflects investor expectations for the potential of FSD Pharma's research and development in neuroscience and other therapeutic areas.
P/S of the market as a whole
FSD Pharma is a biopharmaceutical company focused on developing drugs for the treatment of inflammatory diseases and central nervous system disorders. This market revenue valuation chart helps understand how investors view the company's scientific developments and its potential in these complex areas of medicine.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company HUGE
FSD Pharma is a biopharmaceutical company focused on developing drugs for the treatment of inflammatory diseases of the central nervous system. This chart shows how the market assesses the future commercial potential of its developments. It reflects investor expectations for the success of clinical trials and the market launch of new treatments.
%20P%2FS%20HUGE&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-HUGE&v=1772565450494 "The graph of the company's future (projected) P/S HUGE")
Future (projected) P/S of the market segment - Pharma neurology
FSD Pharma is a biopharmaceutical company focused on developing drugs for the treatment of inflammatory diseases and central nervous system disorders. The company's valuation, like many clinical-stage companies, is based on investors' faith in the scientific potential of its developments and is associated with high risks associated with clinical trials.
%20P%2FS%20market%20segment%20graph%20-%20Pharma%20neurology&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Pharma-neurology&v=1772565450505 "Future (projected) P/S market segment graph - Pharma neurology")
Future (projected) P/S of the market as a whole
FSD Pharma is a biopharmaceutical company focused on developing drugs for the treatment of neurological diseases. Its prospects depend on the success of clinical trials. In the context of the overall revenue projections shown in the chart, HUGE represents a venture investment in the future of neuroscience.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772565450572 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales HUGE
FSD Pharma is a biopharmaceutical company specializing in the development of drugs for the treatment of central nervous system disorders. Being in the clinical stage, the company has no commercial revenue from product sales. Any revenue shown in the chart likely comes from licensing or partnership deals.
Sales of companies in the market segment - Pharma neurology
FSD Pharma (HUGE) is a biopharmaceutical company focused on developing drugs for the treatment of inflammatory and central nervous system diseases. This metric reflects revenue in the pharmaceutical sector. FSD Pharma strives to develop innovative treatments for conditions with high unmet medical need.
Overall market sales
FSD Pharma is a biopharmaceutical company developing drugs for the treatment of neurological disorders. Its future depends on the results of clinical trials. This pattern of overall economic activity influences the investment climate in the biotech industry. During periods of growth, investors are more willing to fund companies working on complex CNS diseases.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company HUGE
FSD Pharma is a biopharmaceutical company focused on developing drugs for the treatment of inflammatory diseases. Its future revenue depends on the success of its clinical trials. This chart reflects analyst forecasts, which essentially assess the scientific potential and commercial prospects of its developments in neurology and inflammation.
%20sales%20of%20the%20company%20HUGE&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-HUGE&v=1772565450795 "Schedule of future (projected) sales of the company HUGE")
Future (projected) sales of companies in the market segment - Pharma neurology
FSD Pharma is a biopharmaceutical company developing drugs for the treatment of inflammatory diseases. The forecast on this chart reflects the potential future revenue from their pipeline of candidates. This is an analyst's view of the commercial prospects of their research and development projects in neuroscience and other therapeutic areas.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Pharma%20neurology&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Pharma-neurology&v=1772565450880 "Schedule of future (projected) sales of companies in the market segment - Pharma neurology")
Future (projected) sales of the market as a whole
FSD Pharma is a biopharmaceutical company focused on developing drugs for the treatment of inflammatory diseases. Its future depends on the success of clinical trials. This chart illustrates the overall investment climate, but for FSD Pharma, the key factor is scientific proof of the efficacy of its molecules, which could attract the interest of investors and partners.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772565450937 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality HUGE
FSD Pharma is a biopharmaceutical company focused on developing drugs for the treatment of inflammatory diseases. While in clinical trials, it incurs significant R&D expenses. The chart shows current profitability as an investment in the development of new treatments that could generate significant future profits.
Market segment marginality - Pharma neurology
FSD Pharma is a Canadian biopharmaceutical company focused on developing drugs for the treatment of inflammatory diseases. This chart reflects its operating expenses during the clinical trial stage. Future profitability is entirely dependent on the success of its scientific developments and regulatory approvals.
Market marginality as a whole
FSD Pharma is a biopharmaceutical company focused on developing drugs for the treatment of neurological diseases. It is currently in clinical trials. This total return chart reflects the investment climate. In a favorable economic environment, when investors are confident about the future, companies like FSD Pharma have an easier time raising capital for research.
Employees in the company, segment and market as a whole
Number of employees in the company HUGE
FSD Pharma is a Canadian biopharmaceutical company focused on developing drugs for the treatment of central nervous system disorders. This graph shows a small research team working to advance their research through early-stage clinical trials.
Share of the company's employees HUGE within the market segment - Pharma neurology
FSD Pharma is a biopharmaceutical company developing drugs for the treatment of neurological disorders. During clinical trials, its staff consists of a team of scientists and R&D specialists. This chart shows the company's human resources dedicated to research in one of the most complex areas of medicine.
Number of employees in the market segment - Pharma neurology
FSD Pharma is a biopharmaceutical company focused on neuroscience. This chart, showing employment in the neuroscience pharmacology sector, illustrates the enormous need to treat diseases of the central nervous system. For FSD Pharma, the growing number of researchers in this complex field means both accelerated science and intense competition for breakthrough ideas.
Number of employees in the market as a whole
FSD Pharma is a biopharmaceutical company developing drugs for the treatment of neurological disorders. Like any development-stage company, it relies on capital to fund research. A strong economy, reflected by rising overall employment in this chart, creates more favorable conditions in capital markets for funding such long-term research projects.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company HUGE (HUGE)
FSD Pharma (HUGE) is a biopharmaceutical company focused on neuroscience. This metric, for a development-stage biotech, is an indicator of concentrated value. Market value is based on expectations for clinical trials and the value of patents. A small team of scientists can create an asset worth billions.
%20of%20the%20company%20HUGE%20(HUGE)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-HUGE-HUGE&v=1772565451569 "Chart of market capitalization per employee (in thousands of dollars) of the company HUGE (HUGE)")
Market capitalization per employee (in thousands of dollars) in the market segment - Pharma neurology
FSD Pharma is a biopharmaceutical company developing drugs for neurological disorders. Its value is determined by its pipeline of potential drugs. This chart demonstrates the high future value the market attributes to its clinical development pipeline, based on its small scientific team.
%20by%20market%20segment%20-%20Pharma%20neurology&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Pharma-neurology&v=1772565451621 "Market capitalization per employee (in thousands of dollars) by market segment - Pharma neurology")
Market capitalization per employee (in thousands of dollars) for the overall market
FSD Pharma is a biopharmaceutical company focused on developing drugs for the treatment of neurological disorders. Its developments are in the early stages. This chart for FSD Pharma shows a typical biotech picture: a high but speculative market cap per employee, based solely on the potential of its scientific program.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772565451666 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company HUGE (HUGE)
FSD Pharma (ticker HUGE) is a small biotech company, despite its ticker symbol. It's in the R&D stage and has no profit. This chart shows a negative value—the capital burn (loss) per employee during neuroscience R&D.
%20Chart%20HUGE%20(HUGE)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-HUGE-HUGE&v=1772565451716 "Company Profit Per Employee (in thousands of dollars) Chart HUGE (HUGE)")
Profit per employee (in thousands of dollars) in the market segment - Pharma neurology
FSD Pharma is a biopharmaceutical company focused on developing drugs for the treatment of neurological disorders. In this complex field of medicine, the effectiveness of the research and development team is critical. This chart reflects the value each employee creates, which is an indicator of the company's productivity in finding new treatments.
%20in%20the%20market%20segment%20-%20Pharma%20neurology&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Pharma-neurology&v=1772565451762 "Chart of profit per employee (in thousands of dollars) in the market segment - Pharma neurology")
Profit per employee (in thousands of dollars) for the market as a whole
FSD Pharma (HUGE) is a biopharmaceutical company that has historically focused on cannabis and is now focusing on developing drugs for neurological disorders. This chart shows the average profitability of one employee in the economy. It provides investors with context: the biotech sector operates in an all-or-nothing paradigm, where the return on personnel (scientists) can be enormous if successful.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772565451852 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee HUGE (HUGE)
FSD Pharma is a biopharmaceutical company focused on developing drugs for the treatment of neurological diseases. Being in clinical development, it has not yet generated commercial revenue from its products. This graph will show zero values, which is typical for R&D companies whose value lies in the potential of their scientific discoveries.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-HUGE-HUGE&v=1772565451942 "Sales chart per company employee HUGE (HUGE)")
Sales per employee in the market segment - Pharma neurology
FSD Pharma (HUGE) is a biopharmaceutical company specializing in the development of drugs for the treatment of neurological disorders and inflammatory diseases. This chart shows the average revenue per employee in the sector. It is important for assessing R&D efficiency and personnel structure compared to other neuroscience biotechs.
Sales per employee for the market as a whole
FSD Pharma (HUGE) is a biopharmaceutical company historically associated with cannabis but has shifted its focus to developing drugs for neurological and inflammatory diseases. This figure is likely low, reflecting the company's transitional phase: investing in new R&D while generating minimal revenue from existing pipelines.
Short shares by company, segment and market as a whole
Shares shorted by company HUGE (HUGE)
FSD Pharma (HUGE) is a Canadian microcap company that started in cannabis and has now shifted its focus to biotech (neurology). This chart shows short interest. The high bearish rates reflect investor skepticism due to the name change, the speculative nature of its new pipeline, and the company's history of unprofitability. (340)
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-HUGE-HUGE&v=1772565452166 "Short Shares Chart for the Company HUGE (HUGE)")
Shares shorted by market segment - Pharma neurology
FSD Pharma (HUGE) is a biopharmaceutical company developing drugs for the treatment of inflammatory diseases and neurological disorders. The chart below represents a general short position in the biotech sector. It demonstrates the general investor skepticism regarding the success of risky clinical trials.
Shares shorted by the overall market
FSD Pharma (HUGE) is a biotech company focused on neuroscience. This chart reflects the overall market pessimism. When fear mounts, investors sell off microcap biotech stocks en masse. They see HUGE as a waste of money on high-risk R&D and prefer to exit the stock without waiting for news on trials in a volatile market.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator HUGE (HUGE)
FSD Pharma is a speculative biotech company known for its shifting focus (from cannabis to psychedelics and neuroscience). It's a "hot news" stock. This indicator is a "fever meter." It "overheats" to the extreme on any announcements of new "breakthrough" R&D and "cools down" when the hype subsides.
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-HUGE-HUGE&v=1772565452318 "RSI 14 indicator chart for the company's stock HUGE (HUGE)")
RSI 14 Market Segment - Pharma neurology
FSD Pharma (HUGE) is a biopharmaceutical company historically associated with cannabis and now focusing on developing drugs for the treatment of inflammatory diseases of the central nervous system. This chart shows the overall momentum in the neurobiological segment. It helps distinguish the reaction to HUGE's news from general euphoria or panic across this complex industry.
RSI 14 for the overall market
FSD Pharma (HUGE) is a biotech company. Like everything in its sector, it's critically dependent on this chart. Market euphoria is an opportunity to easily raise hundreds of millions of dollars for research. Market panic is the risk of running out of money before its breakthrough technologies reach patients.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast HUGE (HUGE)
FSD Pharma (HUGE) is a biotech company focused on developing drugs for the treatment of central nervous system diseases, particularly multiple sclerosis. This chart shows the speculative average 12-month price target from analysts, which is based almost entirely on their assessment of the company's R&D portfolio and clinical trial data.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-HUGE-HUGE&v=1772565452381 "A chart showing analyst consensus forecasts for the expected stock price. HUGE (HUGE)")
The difference between the consensus estimate and the actual stock price HUGE (HUGE)
FSD Pharma (HUGE) is a biotech company developing drugs for the treatment of inflammatory and neurological diseases. This chart shows how the current share price differs from its "fair" value. It reflects analysts' "venture capital" assessment of their R&D portfolio and the chances of clinical success.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-HUGE-HUGE&v=1772565452409 "A chart showing the difference between the consensus forecast and the actual stock price. HUGE (HUGE)")
Analyst consensus forecast for stock prices by market segment - Pharma neurology
FSD Pharma (HUGE) is a clinical-stage biotech focused on treating neurodegenerative and inflammatory diseases. This is a high-risk R&D sector. This chart reflects the collective analyst opinion on the *entire* neuroscience pharma sector. It shows whether experts believe breakthroughs are possible or view the sector as an R&D "graveyard."
Analysts' consensus forecast for the overall market share price
FSD Pharma (HUGE) is a biotech company specializing in developing drugs for the treatment of central nervous system (neurology) diseases. This is a high-risk sector. This chart reflects the overall market "risk appetite." For HUGE, a clinical-stage company, overall market optimism (the rising chart) is critical for raising capital for R&D.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index HUGE
FSD Pharma is a biotech R&D company that has rebooted itself. Having abandoned the hyped cannabis industry, their focus is now on the R&D of innovative molecules (targeting inflammation) for the treatment of complex diseases (MS, depression). This chart is a pure R&D barometer of faith/fear. It doesn't reflect sales, but a speculative assessment of their (very risky) pipeline and clinical data.
AKIMA Market Segment Index - Pharma neurology
FSD Pharma (HUGE) is a biopharmaceutical company focused on neuroscience and inflammatory diseases. They develop drugs to treat complex conditions such as multiple sclerosis. This chart compares their composite index to the sector, showing how their neuroscience R&D stacks up against others.
The AKIM Index for the overall market
FSD Pharma is a biotech company developing treatments for neurodegenerative and metabolic diseases. It also has a history in cannabis. This chart, which reflects the market average, provides a macro backdrop. It helps assess how a HUGE, speculative microcap stock compares to overall economic trends.
